Global Preclinical CRO Research Report 2025 (Status and Outlook)
Report Overview:
Preclinical Contract Research Organizations (CROs) are specialized service providers that support pharmaceutical, biotechnology, and medical device companies in conducting research and development activities before the clinical testing phase of their products. These organizations typically offer a range of services, including drug discovery, preclinical testing, safety assessments, and efficacy evaluations. The goal of preclinical CROs is to help companies identify potential risks, optimize drug formulations, and comply with regulatory requirements before entering clinical trials. This sector plays a crucial role in the early stages of drug development by offering specialized expertise, technical capabilities, and resources to reduce the risks associated with the transition from the laboratory to clinical testing.
In 2024, the global preclinical CRO market reached USD 16,345 million and is projected to expand at a CAGR of 8.34% from 2025 to 2035, reaching USD 39,769 million by 2035. This growth is driven by a combination of expanding demand, technological innovation, global resource optimization, and the widespread adoption of outsourcing. Over the past decade, the steady rise in global innovative drug R&D has strongly propelled the preclinical CRO market. At the core of this trend is the continuously increasing investment in innovative drug development, fueled by rising healthcare needs, population aging, and the complexity of chronic and rare diseases, which generates long-term, stable demand for preclinical services. Small and mid-sized biotech firms with limited internal capabilities heavily rely on CROs for specialized support, while large pharmaceutical companies increasingly outsource non-core preclinical stages, further amplifying overall market demand. Moreover, breakthroughs in AI, gene editing, and organoid platforms have not only accelerated preclinical workflows and improved predictability but also enabled CROs to deliver high-value integrated services, enhancing client stickiness and competitive advantage. At the same time, the globalization of drug development is prompting CROs to build cross-regional networks, optimize resource allocation, balance cost-efficiency, and mitigate operational risks, with emerging markets such as China and India becoming key growth centers. Beyond these structural drivers, the rise of outsourcing allows pharmaceutical companies to convert fixed costs into flexible, scalable solutions, alleviating financial and operational pressures while improving capital efficiency.
Despite strong market growth and ongoing technological advancement, the preclinical CRO sector faces significant challenges. Rapid technological iteration provides opportunities to enhance efficiency and expand service capabilities but also entails substantial capital investment and the need for multidisciplinary talent, posing major barriers for small and mid-sized CROs and widening competitive disparities. Concurrently, the global regulatory environment is becoming increasingly stringent. Enhanced GLP standards, more complex ethical review requirements, and regional regulatory differences elevate compliance costs and operational complexity, particularly for companies pursuing multinational expansion. Talent shortages further exacerbate these pressures, driving up labor costs, destabilizing project teams, and compromising service continuity and quality. Additionally, intense market competition and pricing pressures—largely driven by client cost control, bulk contracts, and the internalization of routine experiments—compress margins and challenge profitability for smaller firms. On top of operational and financial pressures, rising expectations for ethical and social responsibility demand increased investment in compliance and technological applications, as societal and regulatory scrutiny around animal welfare and alternative testing methods intensifies.
Segmented by service type, the preclinical CRO market includes Bioanalysis and DMPK Studies, Toxicology Testing, Safety Pharmacology, and other services. The market exhibits notable concentration, particularly in high-value service areas. Bioanalysis and DMPK Studies hold the largest market share and demonstrate strong growth potential; by 2024, they are expected to account for 42.6% of the market, reflecting robust demand for precise pharmacokinetic and pharmacodynamic data, which are essential for early-stage drug development decisions. This dominance arises from pharmaceutical companies’ increasing reliance on rigorous bioanalytical evaluations to optimize dosing, assess metabolism, and mitigate downstream clinical trial risks, making these services indispensable within innovative drug pipelines. Meanwhile, Safety Pharmacology and other specialized services are projected to achieve the fastest CAGRs by 2035—9.47% and 9.74%, respectively—highlighting the growing need for complex, high-precision testing, including organoid-based assays, immunogenicity evaluation, and integrated biomarker studies.
From an end-user perspective, pharmaceutical companies are the primary drivers of the preclinical CRO market, accounting for 82.8% of total revenue in 2024. This segment’s strong growth—forecasted to reach a CAGR of 8.59% through 2035—is underpinned by the increasing complexity of innovative drug R&D, encompassing biologics, gene and cell therapies, and high-value small molecules that require extensive preclinical evaluation to optimize safety, efficacy, and regulatory compliance.
Geographically, the market is shifting toward the Asia-Pacific region, which accounted for 36.97% of the market in 2024 and is expected to maintain the fastest growth at a CAGR of 10.2% through 2035. This growth is supported by lower operational costs, expanding local biopharmaceutical ecosystems, and rising demand from emerging biotech firms. According to TrialiCube, mainland China has become the leading region for clinical trial initiation, surpassing Europe in 2021 and the United States in 2023, driven by its highly efficient R&D capabilities and cost-effectiveness. North America and Europe remain key market hubs, representing over 58% of total market share in 2024, but their growth is more moderate, at 7.07% and 6.62% respectively, reflecting market maturity and rising labor and facility costs.
Preclinical CRO Industry Chain Analysis
Key Development Trends
Global Innovative Drug Clinical Trials on the Rise
The number of global innovative drug clinical trials has shown a steady upward trend over the past decade. The number of industry-sponsored trials (IST) initiated annually increased from 3,788 in 2015 to 4,678 in 2024, representing a 23.5% growth over ten years. Among these, Phase I trials accounted for the largest share, rising from 39% in 2015 to 47% in 2024. In the past two years, Phase II and Phase III trials have each accounted for around 20% of the total. The following shows the number of global innovative drug clinical trials and the proportion of each phase from 2015 to 2024:
From the perspective of trial locations: in 2015, the number of innovative drug clinical trials conducted in mainland China was significantly lower than in the United States and Europe. However, over the past decade, the number of trials in mainland China grew rapidly, surpassing Europe in 2021 and the U.S. in 2023, and has now become the region with the highest number of clinical trials globally. In 2024, mainland China initiated 2,069 new innovative drug clinical trials, accounting for 44% of the global total that year.
According to McKinsey, Chinese companies demonstrate remarkable efficiency in the drug discovery phase. From target identification to IND submission, the R&D speed of Chinese companies can be 2–3 times faster than the global standard, while costs are only one-third to one-half of the international best levels. For example, for fast-follow small molecule drugs, Chinese companies compress the stages of preclinical candidate selection and IND application to 6–9 months and 9–12 months, respectively, saving 50%–70% of the time compared to the global best practice.
The following shows the trend of global innovative drug clinical trials by country from 2015 to 2024:
Technological Innovation Reshaping Market Structure
Beyond traditional toxicology and pharmacokinetics experiments, technological innovations are profoundly altering the service models and technical boundaries of preclinical CROs. On one hand, the introduction of technologies like high-throughput screening, AI predictive models, and modern in vitro 3D organ models has significantly reduced the need for animal experiments while enhancing model reliability and predictability. For example, organoid technology provides a viable solution to this structural bottleneck: researchers can use patient-derived organoids to construct in vitro disease models for disease mechanism analysis, potential target discovery, and novel biomarker screening. AI has also accelerated preclinical research: unlike earlier stages that were purely data analysis-driven, current AI technologies now integrate both "dry" and "wet" experiments. AI models can merge genomics, proteomics, and phenotypic data to predict drug-target interactions, making target identification 100 times faster, optimizing lead compound efficiency by 30%, and reducing preclinical timelines by 50-80%.
On the other hand, the integration of these technologies not only improves the efficiency of CRO services but also helps pharmaceutical companies make quicker decisions during the preclinical phase, thereby shortening overall R&D timelines and lowering costs. For instance, AI technology can optimize experimental design and data analysis, and high-throughput platforms enable larger-scale data output, which is especially crucial for addressing the development of personalized medicine and precision therapy.
Technological advancements have shifted from being "auxiliary tools" to core competitive capabilities for CROs. This has led to the segmentation of services and the upgrading of value chains within the industry, driving growth in high-value services such as biomarker development and immunotoxicology.
Global Regulatory Coordination and Compliance System Upgrades
As global drug safety awareness continues to rise and the complexity of innovative drugs increases, the regulatory environment for preclinical CROs is becoming increasingly stringent, with a clear trend toward global regulatory coordination. Regulatory agencies across countries and regions are no longer focusing solely on developing independent regulatory standards, but are actively promoting the convergence of international standards to reduce regulatory barriers for new drug approvals and facilitate the global flow of pharmaceutical R&D resources.
Strict regulatory requirements are mainly reflected in two areas: process standardization and technology standard upgrades. In terms of process standardization, regulatory agencies have strengthened oversight of Good Laboratory Practice (GLP) standards, requiring preclinical CROs to ensure traceability, authenticity, and completeness of research data, while enhancing management of animal experiments and ethical reviews. For example, in recent years, China's National Medical Products Administration (NMPA) has further improved its GLP certification system, with only companies that have dual GLP-certified laboratories being eligible to undertake core preclinical safety evaluation projects. Regarding technological standard upgrades, with the advent of new technologies like AI and organoids, regulatory agencies are accelerating the formulation of relevant technical guidelines. For example, in April 2025, the U.S. Food and Drug Administration (FDA) announced the gradual elimination of animal testing requirements for monoclonal antibodies, opting for new technologies such as organoids, organ-on-chip, and AI models to assess drug safety.
Driving Factors
Expansion of Demand for Innovative Drug R&D
From a global macro perspective, the sustained expansion of demand for innovative drug R&D is the core underlying logic for the growth of the preclinical CRO market. This demand fundamentally stems from the unmet global healthcare needs and the inevitable trend of innovation and upgrading within the pharmaceutical industry. As the global population ages, the incidence of chronic and rare diseases increases, and there is an urgent need for treatments for severe conditions like cancer, traditional drugs are no longer sufficient to cover the diverse medical scenarios, prompting pharmaceutical companies to increase their investment in innovative drug R&D. According to statistics and forecasts from Smart Pharma, Frost & Sullivan, and others, global pharmaceutical R&D spending is expected to continue growing, continuously injecting demand into the preclinical CRO market. Below is the worldwide pharmaceutical R&D spending forecast for 2016–2030, as compiled by Smart Pharma:
This demand is not a short-term surge but a rigid need throughout the pharmaceutical industry’s upgrading cycle, providing a long-term and stable growth foundation for the preclinical CRO market. The diversification of targets and technological complexity in innovative drug R&D has further amplified the demand for specialized preclinical CRO services. Over the past decade, innovative drug R&D has expanded from traditional small molecule drugs to more complex areas like biologics, cell and gene therapy (CGT), and antibody-drug conjugates (ADCs). The R&D processes for these types of drugs are more intricate and have higher technical barriers, significantly increasing the need for specialized and precise preclinical research.
Additionally, the explosive growth of biopharmaceutical companies, particularly the rise of small and mid-sized biotech firms, has become a key growth driver for the preclinical CRO demand. Compared to large pharmaceutical companies, small and mid-sized biotech firms focus on niche innovation, benefiting from flexible R&D processes and efficient decision-making. However, they typically face challenges such as limited funding, incomplete technical platforms, and a lack of extensive R&D experience, which makes them more reliant on preclinical CRO services. In the Asia-Pacific region, for example, the rapid expansion of the biopharmaceutical sector has directly driven the growth of the preclinical CRO market, as emerging biotech companies push the demand. Meanwhile, large pharmaceutical companies, focusing on core R&D areas, are gradually outsourcing non-core preclinical stages, forming a "self-research + outsourcing" collaborative model that further amplifies the overall market demand.
The active global pharmaceutical transaction market has also indirectly stimulated the release of preclinical CRO demand. In recent years, mergers and acquisitions, as well as license-in/out transactions in the pharmaceutical field, have surged. Companies involved in these transactions need to conduct a significant amount of preclinical research to validate the value of drugs before and after the deal, such as candidate compound screening, safety evaluation, and efficacy verification. For example, some biotech companies, before licensing their core pipelines to large pharmaceutical companies, need to commission CROs to complete comprehensive preclinical toxicology studies and pharmacokinetic analyses to meet transaction valuation and subsequent R&D requirements. This transaction-driven demand, combined with ongoing R&D needs, forms a dual support system for the growth of the preclinical CRO market.
Technological Innovation
Technological innovation is the core engine driving high-quality growth in the preclinical CRO market. Its main value lies in addressing the industry pain points of traditional preclinical R&D—long cycles, high costs, and low success rates—while reconstructing R&D service models and industry value chains.
Traditional preclinical research relies heavily on manual operations and experience-based judgment, leading to low screening efficiency, poor experimental reproducibility, and clinical translation rates below 10%. The deep application of new technologies such as AI, gene editing, and organoids has enabled simultaneous improvements in R&D efficiency and precision, creating differentiated competitive advantages for CROs and attracting more pharmaceutical companies to outsource services. The integration of AI with big data technologies optimizes efficiency across the entire preclinical R&D process. Big data also enables standardized management and deep mining of experimental data, providing scientific support for subsequent clinical research and further enhancing the value of preclinical studies.
Breakthroughs in emerging biotechnologies, such as gene editing and organoids, have driven iterative upgrades in preclinical research paradigms. Gene-editing technologies like CRISPR-Cas9 can rapidly construct precise disease animal models, addressing the significant differences between traditional models and human physiology, shortening preclinical cycles for targeted drugs by 70%. Patient-derived organoid (PDO) models replicate human functions with over 80% accuracy, effectively reducing the risk of clinical trial failures and are recognized by regulatory agencies like the FDA, becoming important data support for drug submissions.
Moreover, the trend toward technological platforms and integration further strengthens CROs’ core competitiveness and client stickiness. Leading CROs have continuously invested in technology platforms covering drug discovery, safety evaluation, and pharmacokinetic research, providing clients with “one-stop” technical solutions, avoiding the communication costs and technical transfer risks associated with multiple collaborators.
Regional Coordination and Optimized Resource Allocation
The continuous deepening of global pharmaceutical industry division is a key driver for the expansion and optimization of the preclinical CRO market. The core logic lies in achieving optimized resource allocation through global deployment, balancing cost control, market expansion, and risk diversification. As the pharmaceutical industry becomes increasingly globalized, companies’ R&D, manufacturing, and sales operations are no longer regionally restricted, requiring CROs to provide global service support. Preclinical CROs are gradually building global service networks through overseas deployment and multinational collaborations, forming an industrial pattern of “regional complementarity and global coordination.”
Cost advantages and growing demand in emerging markets are driving global preclinical CRO resources toward regions like Asia-Pacific. Although mature markets such as North America and Europe remain the core global preclinical CRO markets, rising labor, R&D, and facility costs, coupled with market saturation, have slowed growth. In contrast, emerging markets such as China and India, with lower labor costs, mature industrial infrastructure, and rapidly growing local demand, have become the core destinations for global CRO industry relocation.
This regional shift not only reduces overall global pharmaceutical R&D costs but also activates demand potential in emerging markets. The global deployment and capability integration of leading CROs improve the completeness of global service networks. To meet the global R&D needs of multinational pharmaceutical companies, leading CROs accelerate overseas expansion through self-built operations or acquisitions, establishing multi-region service centers to achieve global coordination of technology, talent, and resources. For example, WuXi AppTec has built a global network covering Asia, Europe, and North America, with UK teams responsible for molecular design and candidate screening, and Asian teams handling compound synthesis and experiments, forming a cross-time-zone collaborative R&D model. Charles River Laboratories has established a toxicology research center in China for preclinical safety evaluation, while retaining core technology development and standard-setting operations in North America, achieving regional capability complementarity.
This global layout not only enhances companies’ risk resistance but also strengthens their ability to serve global clients, further consolidating their market-leading positions. Geopolitically driven supply chain decentralization further indirectly supports the global growth of the preclinical CRO market.
Global Preclinical CRO Market: Competitive Landscape
The global preclinical CRO market maintains a moderate concentration level. The top five companies—WuXi AppTec, Labcorp, Charles River, Eurofins Scientific, and PPD (Thermo Fisher Scientific)—are projected to hold a combined market share of 53.4% in 2025, slightly lower than 55.6% in 2024. This gradual decline reflects the ongoing expansion of smaller and regional CROs and the rapid growth of emerging markets. The Herfindahl-Hirschman Index (HHI) similarly indicates a modest decrease to 6.86% in 2025, suggesting that while leading companies remain dominant, market competition is intensifying. Key market participants include WuXi AppTec, Labcorp, Charles River, Eurofins Scientific, PPD (Thermo Fisher Scientific), ICON Plc, Pharmaron, Inotiv, EVOTEC, JOINN Lab, SGS SA, Medicilon, ChemPartner, Crown Bioscience, and The Jackson Laboratory.
Global Preclinical CRO Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Labcorp
Charles River
Eurofins Scientific
PPD (Thermo Fisher Scientific)
ICON Plc
Pharmaron
Inotiv
EVOTEC
JOINN Lab
SGS SA
Medicilon
ChemPartner
Crown Bioscience
The Jackson Laboratory
Market Segmentation (by Type)
Bioanalysis and DMPK Studies
Toxicology Testing
Safety Pharmacology
Others
Market Segmentation (by Application)
Pharmaceutical Companies
Medical Device Companies
Other
Geographic Segmentation
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Key Benefits of This Market Research:
• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Preclinical CRO Market
• Overview of the regional outlook of the Preclinical CRO Market:
Key Reasons to Buy this Report:
• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Preclinical CRO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 details the production of products in major countries/regions and provides the production of major countries/regions.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 13 is the main points and conclusions of the report.
